Health-related quality of life up to 1 year after radiotherapy in patients with head and neck cancer (HNC) by unknown
Loorents et al. SpringerPlus  (2016) 5:669 
DOI 10.1186/s40064-016-2295-1
RESEARCH
Health-related quality of life up to 
1 year after radiotherapy in patients with head 
and neck cancer (HNC)
Vera Loorents1*, Johan Rosell2, Helen Salgado Willner1 and Sussanne Börjeson1,3
Abstract 
Background: Detailed symptom specific descriptions of health-related quality of life (HRQOL), using validated ques-
tionnaires in patients with head and neck cancer (HNC) are sparse. The aim of the present study was to investigate 
HRQOL in patients with HNC up to 1 year after radiotherapy (RT), using two standardised questionnaires.
Methods: The data for the present study was originally collected in a randomised, prospective study. Forty-seven 
patients from two RT clinics in Sweden were included to investigate the secondary aim: HRQOL. Data was recorded at 
baseline, completion of RT, and 3, 6, 12 months after completed RT, using the questionnaire EORTC QLQ-C30-version 
3 and the disease-specific module EORTC QLQ-H&N35.
Results: Most symptoms and functions deteriorated significantly by the end of RT, improved gradually by 3 and 
6 months and reached baseline levels at 12 months after completed RT. However, 1 year after completed RT there 
were remaining significant problems in senses, dry mouth and sticky saliva.
Conclusions: Radiation therapy affects health-related quality of life in patients with head and neck cancer, both in 
the short and long term. Caregivers need management strategies for early detection and treatment of specific prob-
lems throughout the treatment period to help in the prevention of long-term symptoms.
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Background
In Sweden, approximately 1200 individuals are diagnosed 
with HNC every year. Standard treatments for patients 
with HNC include RT, with or without surgery, and/or 
combined chemotherapy (CT) (Socialstyrelsen 2011). 
Advancements in RT treatment techniques in patients 
with HNC have resulted in better survival rates (Beadle 
et  al. 2014) but have also induced challenges related to 
management of acute and late side effects of RT. Some of 
these side effects can be objectively observed, but many 
of them can only be measured by the patients themselves. 
Quality of life questionnaires measuring symptoms of 
the disease and side effects of treatment gives the patient 
a structured tool for expression and provides health 
caregivers with valuable information on patient reported 
outcomes. This ultimately enhances the understanding 
of patient burden in the development of new treatment 
techniques.
Health-related quality of life (HRQOL) is defined as 
a specific subset of quality of life, assessing symptoms, 
psychological aspects, and function (Fayers and Machin 
2007). Overall HRQOL in patients with HNC has been 
assessed in several studies using the validated EORTC 
QLQ-C30 and QLQ-H&N35 instruments (Aaronson 
et  al. 1993; Bjordal et  al. 1999). Results from previous 
studies on HRQOL have shown that most of the patient’s 
function, symptom and global health scales show dete-
rioration at the completion of RT and then an improve-
ment by 3 and 6  months after completed RT (Chandu 
et al. 2006; Murphy et al. 2007; Sherman and Simonton 
2010; So et  al. 2012). Some symptoms including xeros-
tomia, changes in taste and smell, sticky saliva and 
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deterioration in physical functioning are still remaining 
up to 12 months after completed RT (So et al. 2012). A 
review reporting on patient-reported late side effects of 
RT from 12 months to 5 years after completed treatment 
showed worsening of role functioning, sticky saliva, nau-
sea and trismus (Sherman and Simonton 2010). Despite 
the fact that studies in the past 20 years have been report-
ing on aspects of HRQOL among patients with HNC 
(Bjordal et  al. 1994, 2001; de Graeff et  al. 2000; Rathod 
et  al. 2013), few studies have monitored patients with 
close follow-ups over time from the completion of RT up 
to 1 year after RT, using all the HRQOL aspects outlined 
in the EORTC QLQ-C30 and QLQ-H&N35. Detailed 
follow-up is important if health care providers are to suc-
ceed in supporting specific needs at specific time points 
in the patient recovery.
The data for the present study was collected in a ran-
domised, prospective study investigating the effective-
ness of a training intervention to prevent trismus in 
patients undergoing RT and up to 12 months after com-
pleted RT (primary endpoint). No statistically significant 
differences in trismus were found between the interven-
tion and control groups (Loorents et al. 2014).
Thus, the aim of the present study was to investigate 
HRQOL in patients with HNC over time and up to 1 year 
after RT, using two standardised questionnaires.
Methods
Study design and participants
This is a longitudinal descriptive study including patients 
with HNC receiving RT. Head and neck cancer is defined 
as a tumour arising from the mucosal surfaces of the 
lip, oral cavity, pharynx, larynx or cervical oesophagus. 
Other sites included are the nose/paranasal sinuses, and 
salivary/thyroid/parathyroid glands (MeSH Browser 
1997). Sixty-six consecutive patients from two differ-
ent RT clinics in Sweden were initially included between 
2009 and 2013. Out of these, 47 completed the 12-month 
follow-up time period and were therefore included in the 
present study.
Inclusion criteria
Patients were included if they were willing to participate, 
>18  years, and able to understand and communicate in 
Swedish. Other study criteria are outlined in the report 
from the main study (Loorents et al. 2014).
Study procedures
Radiotherapy and treatments
All 47 patients received external beam radiotherapy 
(RT). Treatment regimens were given in accordance with 
tumour size, site and stage of disease. Radiotherapy was 
administered in either curative or palliative intentions, 
pre or post-surgery. Therapy doses ranged between 46 
and 70 Gy given in 2 Gy daily, 5 days a week. Treatment 
techniques included 3D-CRT or IMRT.
Data collection
Demographic variables, listed in Table  1, were col-
lected in a written questionnaire, while clinical data was 
extracted from patient medical records.
Health‑related quality of life assessments
Health-related quality of life was assessed at five different 
points; baseline, at completion of RT, 3, 6, and 12 months 
after completed RT, using the self-administered EORTC 
QLQ-C30-version 3 and the disease specific module 
EORTC QLQ-H&N35. The baseline measurement was 
assessed the week prior to RT start. Patients received 
their first two questionnaires from their contact nurse. 
After completion of RT, the questionnaires were sent by 
post together with a pre-paid return envelope addressed 
to one of two assessors. A reminder questionnaire was 
sent to non-responders. A total of 330 questionnaires 
plus reminder questionnaires were distributed. Dates for 
Table 1 Patient characteristics (n = 47)





Age (mean, SD, range) 63.13, 11.3, 24–88
Tumour site
 Base of tongue 8
 Tongue 2
 Nasal cavity 1
 Floor of mouth 2










 Missing data 9
External beam radiotherapy (RT)
 3D conformal radiotherapy (3DCRT) 24
 Intensity-modulated radiotherapy (1MRT) 23
 Concomitant chemotherapya 27
 No chemotherapy 20
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distribution of the questionnaires were calculated from 
the date for the baseline questionnaire.
The European Organisation for the Research and Treat-
ment of Cancer’s Quality of Life Questionnaire, Core-
30-version 3 (EORTC QLQ-C30), and specific module 
Head and Neck 35 (EORTC QLQ-H&N35) are proven 
to be robust instruments and have a widespread clinical 
usage. The core instrument EORTC QLQ-C30 is used 
in conjunction with site or disease modules to provide a 
more comprehensive assessment of patient reported dif-
ficulties. Established reliability, validity and sensitivity to 
change have been tested in many clinical studies (Aaron-
son et al. 1993; Rathod et al. 2013).
In both questionnaires a 1-week time frame is used. 
Most questions are answered on a scale from 1 to 4 where 
1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very 
much. Global health status uses numerical scales (1–7), 
where 1 = very poor and 7 = excellent. Some symptom 
questions in the H&N35 module are answered by yes or 
no.
Health-related quality of life scores are then calcu-
lated according to the EORTC QLQ-C30 scoring manual 
EORTC QLQ-C30 (version 3) (Fayers et  al. 2001). All of 
the EORTC scales and single-item score measures are 
converted to a scale ranging from 0 to 100, except the 
global health scales, which range from 1 to 7.
EORTC QLQ‑C30
This core questionnaire includes 30 items, that describe 
5 functioning scales (physical, role, emotional, cognitive, 
and social functioning), 3 symptom scales (fatigue, nau-
sea/vomiting, and pain), and 6 single items symptoms 
(dyspnoea, insomnia, loss of appetite, constipation, diar-
rhoea, and financial difficulties). There is also a global 
health status scale.
Higher scores on the 5 functional and global health sta-
tus scales refer to better health status, while higher scores 
on the symptom scales represent more problems.
EORTC QLQ‑H&N35
This module was developed specifically for patients 
with HNC and contains 35 questions divided into 7 
subscales about pain, swallowing, senses, speech, social 
eating, social contact, and sexuality. There are 10 single 
items relating to problems with teeth, dry mouth, cough, 
mouth opening, sticky saliva, weight loss, and weight 
gain, use of nutritional supplements, feeding tubes, and 
painkillers. Higher scores in this module represent higher 
level of problems.
Sample size calculation and statistical analysis
The sample size was calculated from the main out-
come reported elsewhere (Loorents et  al. 2014). Of the 
original 66 patients, 47 fulfilled the 12-month assessment 
and were therefore included in the present analysis on 
HRQOL. The 19 dropouts were a result of death (n = 5), 
failure to comply (n = 7), logistical problems (n = 1), or 
withdrawal due to patient request (n = 6) (Loorents et al. 
2014). All data was entered into an Access database, and 
all statistical analyses were done with IBM SPSS-(version 
21).
To investigate the differences between study groups, 
the Mann-Whitney U test was used.
For pairwise comparisons the Wilcoxon signed-rank 
test was conducted. All p values were two-sided, and 
results were considered significant at p < 0.05.
Results
A total of 47 patients completed the 12-month follow-up. 
To investigate if we could analyse the data on HRQOL for 
the entire group of patients with HNC, irrespective of the 
original study groups we preformed comprehensive anal-
ysis on differences in HRQOL between the intervention/
control groups from the original study (Loorents et  al. 
2014). No significant differences in any of the functional 
or global HRQOL scales were found between the groups 
However, there were statically significant differences in a 
few of the symptom scales, including:
The control group used more nutritional supplements 
(mean = 63) than the intervention group (mean = 33) at 
baseline (p = 0.018).
The control group self-reported more difficulty in 
opening their mouth (mean = 24) than the intervention 
group (mean = 15) at the completion of RT (p = 0.0039). 
This difference was also found at 3  months after com-
pleted RT, where the control group still had difficulty in 
opening their mouth (mean = 17) compared to the inter-
vention group (mean = 9), (p = 0.031). The intervention 
group had more problems (mean =  5) than the control 
group (mean  =  0) with nausea/vomiting at 12  months 
after completed RT (p = 0.017).
Due to the homogeneity of the two original study 
groups, we decided to analyse the results regarding qual-
ity of life in the entire group of head and neck cancer 
patients, addressing all assessment points, regardless of 
original group affiliation.
Baseline demographic variables for this present study 
group are outlined in Table 1.
Changes over time in HRQOL
There was a significant deterioration from baseline to 
completion of RT in most of the functioning scales, 
resulting in more problems in the physical, role, cognitive 
and social scales (Fig. 1).
There was still a significant worsening from baseline to 
the 3-month follow-up in some of the functioning scales, 
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resulting in problems in, the physical and role function-
ing scales (Fig. 1). This remained at 6 months after com-
pleted RT in the physical and functioning scales.
At 12 months, all of the scales had gradually increased 
to above baseline values.
There was a significant decrease in global health scales 
at the completion of RT compared to baseline. There was 
a significant improvement in global health scales com-
pared to baseline at 3, 6 and 12  months after completed 
RT, resulting in better values than baseline global health 
values (Additional file 1). Some symptoms, single items and 
subscales were significantly increased in both the EORTC 
QLQ-C30-version 3 and EORTC QLQ-H&N35 at the com-
pletion of RT compared to baseline, resulting in problems 
in: fatigue, nausea/vomiting, pain, dyspnoea, appetite loss, 
constipation, mouth opening, dry mouth, sticky saliva, 
coughing, pain killers, nutritional supplements, feeding 
tubes, weight loss, swallowing, senses, speech, social eating, 
social contact, less sexuality, feeling ill (Figs. 2, 3, 4). 
A few of the above items remained a significant prob-
lem at 3 months after completed RT compared to base-
line, namely fatigue, appetite loss, senses, social eating, 
less sexuality, dry mouth, sticky saliva, and dyspnoea 
(Figs. 2, 3, 4).
At 6  months there were still remaining problems in 
fatigue, appetite loss, senses, social eating, dry mouth, sticky 
saliva, and pain killers compared to baseline (Figs. 3, 4).
Remaining significant increases at 12  months were 
found in senses, dry mouth, and sticky saliva, resulting 
in continued problems compared to baseline (Figs. 3, 4). 
Diarrhoea was significantly increased at 3  months after 
completed RT compared to baseline. At 6 months there 
were better values than at baseline, values had normal-
ised at 12 months (Fig. 2).
Discussion
The results of this study show an overall decrease in 
HRQOL at the completion of RT and fast recovery dur-
ing the follow-up year. Several symptoms and functions 
deteriorated significantly by the end of RT, and then 
gradually improved by 3 and 6 months to reach baseline 
levels at 12 months after completed RT.
However, at 1  year after completed RT there were 
remaining significant problems in senses, dry mouth and 
sticky saliva.
We chose to analyse the patients over time, irrespec-
tive of the original study group, as there were only small 
statistically significant differences between the origi-
nal intervention and control groups. We were surprised 
about the significant differences in self-reported mouth 
opening between the two groups as we in the main study 
(Loorents et al. 2014) did not find significant differences 
in the same patients using standardised, objective meas-
urements. Although the differences were statistically sig-
nificant they were small and of little clinical relevance, 
which supports our conclusion in the main study that 
mouth opening training cannot be recommended for all 
patients receiving RT.
Fig. 1 Functional scales of the EORTC QLQ C-30 (0–100 point scale) from baseline over a 12-month period. Mean values based on patients answer-
ing the questionnaire. Higher scores indicate a high level of function. Statistically significant differences compared to baseline: <0.001 at completion 
of RT in physical, role, and social scales; <0.05 at completion of RT in cognitive scale; <0.001 at 3 months after RT in physical scale; <0.05 at 3 months 
in role scale; <0.001 at 6 months in physical scale; <0.05 at 6 months in emotional scale; <0.05 at 12 months in emotional scale
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The present study has a more positive outcome on global 
health over time than other studies that have reported on 
a more gradual increase in global health scales over time 
from baseline and after completed RT (Murphy et al. 2007; 
So et al. 2012). The slight decrease in global health values 
observed at the completion of RT in this study may have 
been the result of a higher usage of feeding tubes at this 
measuring point. One review (Murphy et  al. 2007) sug-
gested that feeding tubes are the single most powerful pre-
dictor for worsened QoL after RT. Overall global health 
Fig. 2 Symptom scales of the EORTC QLQ C-30 (0–100-point scale) from baseline over a 12-month period. Mean values based on patients answer-
ing the questionnaire. Higher scores indicate more severe symptoms or impairments. Statistically significant differences compared to baseline: 
<0.001 at completion of RT in fatigue, appetite loss, and constipation; <0.05 at completion of RT in nausea, pain, and dyspnoea; <0.001 at 3 months 
after RT in fatigue, and appetite loss; <0.05 at 3 months in dyspnoea, and diarrhoea; <0.05 at 6 months in fatigue, and appetite
Fig. 3 Symptom scales of the EORTC QLQ-H&N35 (0–100-point scale) from baseline over a 12-month period. Mean values based on patients 
answering the questionnaire. Higher scores indicate more severe symptoms or impairments. Statistically significant differences compared to base-
line: <0.001 at completion of RT in pain, swallowing, senses, social eating, and sexuality; <0.05 at completion of RT in social contact, and speech; 
<0.001 at 3 months after RT in senses, and social eating; <0.05 at 3 months in sexuality; <0.001 at 6 months in senses; <0.05 at 6 months in social 
eating; <0.001 at 12 months in senses
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improvement may also be explained by patients’ adjust-
ment to a new life situation and life appraisal. We assume 
that a patient who has learnt to cope adjusts better to 
their situation. Sherman and Simonton (2010), reported 
on how patients cope with HNC, suggesting that patients 
undergoing treatments use the greatest number of cop-
ing strategies. Hammerlid and Taft (2001), reporting on 
a comparison between HNC patients and the general 
Swedish population with regard to HRQOL 3 years after 
treatments, showed that patients with HNC still suffer 
functional problems related to their disease/treatments. 
However, these problems do not generally affect their 
overall HRQOL, which suggests that patient have success-
fully adjusted to living with their problems.
Patients’ grading of the function scales were high 
at baseline. The largest decrease was reported in role 
and social functioning, which was only fully restored 
at the 6-month assessment. All function scales were 
above baseline values at 12  months. Some studies have 
reported on a decrease in physical functioning remaining 
at 12 months and up to 5 years (Sherman and Simonton 
2010; So et al. 2012), while Murphy et al. (2007) reported 
on QoL declining immediately after therapy (RT +  sur-
gery) and returning towards baseline by 1  year (Addi-
tional file 1).
Emotional role was scored higher than expected at 
baseline (indicating fewer problems) in the present 
study, reaching significantly better values than baseline 
levels at 6 months. This low incidence of emotional role 
problems may have to do with the fact that there were 
more men included in the study; one study reported that 
women have more problems with emotional role (Ham-
merlid et al. 2001). A review from 2010 (So et al. 2012) 
reported an emotional function scoring deterioration 
during RT and a stabilisation at 12 months. Our patients 
were all offered professional counselling by hospital 
counsellors, as part of our hospitals standard care at the 
time of their cancer diagnosis. This may be a contribut-
ing factor to the positive emotional function scores in 
the present study.
Cure and tumour control has been the focus of HNC 
management, with less focus on quality of life and reha-
bilitation. In daily clinical work, improvements in quality 
assessments of oral function during and after treatments 
are needed to help manage oral function and prevent 
chronic sequelae. The remaining chronic problems in 
senses, dry mouth and sticky saliva observed in the pre-
sent study have been reported in other studies (Bjordal 
et  al. 1994, 2001). One review reported that the best 
results for reducing acute oral toxicities of cancer thera-
pies are achieved with a multidisciplinary health care 
team who communicate effectively to coordinate patient 
care (Epstein et  al. 2012). Good communication and 
access to HRQOL data may play a role in QoL issues for 
HNC patients. There is indication of a positive therapeu-
tic effect on HRQOL in HNC patients who experience 
that their physicians have access to OoL data and use 
this information in their communication (Murphy et  al. 
2007).
Health care providers need to address what types of 
interventions are needed and when they are needed 
in the supportive care for these patients. Are men and 
Fig. 4 Symptom scales of the EORTC QLQ-H&N35 (0–100-point scale) from baseline over a 12-month period. Mean values based on patients 
answering the questionnaire. Higher scores indicate more severe symptoms or impairments. Statistically significant differences compared to base-
line: <0.001 at completion of RT in dry mouth, sticky saliva, weight loss, and nutritional supplements; <0.05 at completion of RT in feeling ill, pain 
killers, feeding tubes, mouth opening, and coughing; <0.001 at 3 months after RT in dry mouth, and sticky saliva; <0.001 at 6 months in dry mouth, 
and sticky saliva; <0.05 at 6 months in pain killers; <0.001 at 12 months in dry mouth, and sticky saliva
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women’s needs different? What do patients perceive as 
problems? For example a recent review reported poorer 
QoL in women (Sherman and Simonton 2010). In our 
study only eight women participated making it impos-
sible to do further analysis regarding gender differences, 
but it needs to be addressed in future studies. Percep-
tions of complications after RT was investigated among 
33 patients after RT, showing that lethargy, weakness, dry 
mouth, mouth sores, pain, taste changes, and sore throat 
were the most debilitating side effects, particularly oro-
pharyngeal mucositis (Rose-Ped et al. 2002).
Study strengths
The main strength of the present study is the complete in-
depth presentation of the whole quality of life tool. There 
is data for all 47 patients who completed all the measure-
ments, which provides a stable analysis of changes over 
time.
Study limitations
Even though prospective data was used in the data col-
lection, the original study design was to test two groups. 
This needs to be taken into account when interpreting the 
results. There may not be enough power in the analysis to 
support the secondary aim of this study group, although 
this may be justified by the significant number of differ-
ences found over time. This was a selected group as some 
patients were excluded from participation in the main 
intervention study. For example, no edentulous patients 
were included.
Conclusion and clinical implications
The present study highlights the different problem areas 
in HRQOL over time, both in the short and long term, 
in patients with head and neck cancer. This is important 
information when planning the time for implementation 
of an intervention in supportive care. Caregivers need 
management strategies for specific problems throughout 
the treatment period to help with the prevention of long-
term symptoms. Caregivers need management strategies 
for early detection and treatment of specific problems 
throughout the treatment period to help in the preven-
tion of long-term symptoms.
Future studies
Future prospective studies are needed to identify factors 
associated with more impaired HRQOL and effective inter-
ventions against the problem areas highlighted by patients. 
Furthermore, there is a need to compare similarities and 
differences in patient-reported outcomes, such as assess-
ment of mouth opening with standardised measurements.
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